Skip to main content

Table 4 Subgroup analyses by cancer type under the allelic, carrier and homozygotic models

From: Association of human XPA rs1800975 polymorphism and cancer susceptibility: an integrative analysis of 71 case–control studies

Models

Subgroup

Study number (case/control)

OR (95% CI)

z

P

Allelic model (G vs. A)

Lung cancer

19 (5004/9162)

0.95 (0.8–1.02)

1.42

0.155

LSCC

3 (878/19,47)

0.91 (0.77–1.08)

1.08

0.282

NSCLC

3 (928/1766)

1.00 (0.75–1.34)

< 0.01

0.999

LA

3 (968/1947)

0.98 (0.86–1.11)

0.35

0.729

Breast cancer

6 (2530/2940)

1.00 (0.83–1.20)

< 0.01

0.998

Digestive system cancer

18 (4038/6811)

1.13 (0.96–1.34)

1.48

0.138

Esophageal cancer

10 (2515/4002)

1.06 (0.82–1.39)

0.47

0.642

ESCC

4 (1136/2239)

1.09(0.76–1.56)

0.45

0.654

Gastric cancer

4 (828/1495)

1.14 (0.83–1.58)

0.82

0.412

Colorectal cancer

3 (593/1021)

1.20 (1.03–1.40)

2.31

0.021

Reproductive system cancer

5 (1429/1756)

1.10 (1.98–1.24)

1.54

0.123

Endometrial cancer

3 (1182/1244)

1.09 (0.89–1.33)

0.86

0.390

Head and neck cancer

4 (886/2289)

1.08 (0.96–1.22)

1.34

0.179

Skin cancer

6 (3874/3826)

1.17 (1.09–1.25)

4.60

< 0.001

Skin BCC

3 (1852/1669)

1.18 (1.07–1.31)

3.23

0.001

Carrier model (G vs. A)

Lung cancer

19 (5004/9162)

0.97 (0.92–1.03)

0.94

0.345

LSCC

3 (878/19,47)

0.94 (0.83–1.08)

0.87

0.386

NSCLC

3(928/1766)

0.97 (0.84–1.12)

0.42

0.675

LA

3 (968/1947)

0.99 (0.86–1.14)

0.14

0.891

Breast cancer

6 (2530/2940)

1.00 (0.91–1.10)

0.03

0.977

Digestive system cancer

18 (4038/6811)

1.09 (1.02–1.17)

2.49

0.013

Esophageal cancer

10 (2515/4002)

1.09 (1.00–1.19)

2.00

0.046

ESCC

4 (1136/2239)

1.06 (0.93–1.20)

0.88

0.379

Gastric cancer

4 (828/1495)

1.04 (0.89–1.20)

0.47

0.637

Colorectal cancer

3 (593/1021)

1.12 (0.94–1.33)

1.29

0.199

Reproductive system cancer

5 (1429/1756)

1.07 (0.95–1.21)

1.15

0.251

Endometrial cancer

3 (1182/1244)

1.08 (0.94–1.24)

1.07

0.285

Head and neck cancer

4 (886/2289)

1.07 (0.93–1.22)

0.93

0.355

Skin cancer

6 (3874/3826)

1.12 (1.03–1.21)

2.82

0.005

Skin BCC

3 (1852/1669)

1.13 (1.01–1.26)

2.05

0.040

Homozygotic model (GG vs. AA)

Lung cancer

19 (5004/9162)

0.87 (0.77–0.99)

2.15

0.032

LSCC

3 (878/19,47)

0.81 (0.59–1.12)

1.27

0.206

NSCLC

3 (928/1766)

0.91 (0.59–1.41)

0.42

0.677

LA

3 (968/1947)

0.92 (0.71–1.18)

0.66

0.512

Breast cancer

6 (2530/2940)

1.01 (0.70–1.45)

0.06

0.954

Digestive system cancer

18 (4038/6811)

1.35 (0.96–1.89)

1.72

0.086

Esophageal cancer

10 (2515/4002)

1.25 (0.74–2.11)

0.82

0.410

ESCC

4 (1136/2239)

1.31 (0.61–2.81)

0.69

0.489

Gastric cancer

4 (828/1495)

1.13 (0.67–1.93)

0.46

0.648

Colorectal cancer

3 (593/1021)

1.68 (1.15–2.44)

2.70

0.007

Reproductive system cancer

5 (1429/1756)

1.14 (0.90–1.44)

1.05

0.295

Endometrial cancer

3 (1182/1244)

1.12 (0.78–1.60)

0.61

0.541

Head and neck cancer

4 (886/2289)

1.09 (0.85–1.41)

0.67

0.503

Skin cancer

6 (3874/3826)

1.36 (1.17–1.57)

4.11

< 0.001

Skin BCC

3 (1852/1669)

1.40 (1.03–1.89)

2.17

0.030

  1. OR odds ratio, CI confidence interval, LSCC lung squamous cell carcinoma, NSCLC non-small cell lung cancer, LA lung adenocarcinoma
  2. ESCC esophageal squamous cell carcinoma, BCC basal cell carcinoma